#United States #Irvine #Afecta Pharmaceuticals #Neuro-Immuno Modulators #AFX-770

Afecta Pharmaceuticals Secures New Patent

In a significant milestone for neurological and ocular disorder treatments, Afecta Pharmaceuticals has been awarded a new patent by the United States Patent and Trademark Office (USPTO). The patent, officially titled "Inhibition of Glial Cell Activation" (US Patent No. 12,673,957), focuses on a comprehensive library of innovative small molecule neuro-immuno modulators aimed at combating the adverse effects of activated glial cells.

Activated glial cells play a detrimental role in the nervous system, contributing to inflammation and ultimately harming both neural and retinal cells. By inhibiting this activation, Afecta is paving the way for a new approach to treat various chronic neurologic and ocular disorders.

Understanding the Patent's Implications

This composition of matter patent uniquely positions Afecta to leverage multi-targeted small molecules that not only modulate vital neurotransmitters but also impact pro-inflammatory cytokines. The potential applications of these compounds span several degenerative brain disorders, including:

• - Parkinson's Disease
• - Huntington's Disease
• - Alzheimer's Disease

The neuro-immuno modulators were identified through Afecta's proprietary discovery platform, PharmetRx.AI, an advanced technology that has already contributed to discovering numerous other lead compounds currently in various stages of clinical and pre-clinical testing. These include therapies targeting chronic neurological, ophthalmological, and dermatological disorders, and conditions pertinent to women's health.

A Breakthrough in Treatment Paradigms

In a statement addressing the significance of this patent, Dr. Bruce W. Kovacs, President of Afecta, emphasized that "This patent marks a key milestone strengthening our growing portfolio of novel small molecules that modulate the activity of multiple targets within several pro-inflammatory pathways that affect many different organ systems."
Dr. Kovacs also noted that "drugs with multi-target activity are the next generation of therapeutics for these complex disorders."


The lead compound associated with this patent, AFX-770, has already demonstrated promising safety and efficacy outcomes in human clinical trials and is currently undergoing formulation for targeted delivery using Afecta's unique engineered nanomaterials platform.

Looking Ahead

Afecta Pharmaceuticals is setting the stage for a series of innovations aimed at tackling some of the most challenging neurological disorders. As they continue to advance their research and expand their pipeline, the potential benefits for patients suffering from these conditions becomes increasingly promising.

For more detailed information on the AFX-770 program and other initiatives within Afecta's pipeline or the PharmetRx.AI discovery platform, stakeholders are encouraged to get in touch with Afecta Pharmaceuticals directly. This latest patent underscores the vital role of research and development in shaping the future of health care, as multi-target therapies hold great potential for personalized and effective treatment strategies.